Daniela Delbeau-Zagelbaum

Icahn School of Medicine at Mount Sinai — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

2h-index16citations16works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

vaccines and immunoinformatics approaches(16), Immunotherapy and Immune Responses(15), Monoclonal and Polyclonal Antibodies Research(13), SARS-CoV-2 and COVID-19 Research(2), COVID-19 Clinical Research Studies(1)

Publications16 total

T cell epitope mapping reveals immunodominance of evolutionarily conserved regions within SARS-CoV-2 proteome
iScience·2025· 1 citedOpen Access
Supplementary Table5 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig4+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supplementary Table3 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig3 + Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig2 + Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Data from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig6+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supplementary Table4 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig7+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025· 1 citedOpen Access
Supplementary Table1. from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supplementary Table2 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig5+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig1+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Cancer Discovery·2025· 12 cited
T cell epitope mapping reveals immunodominance of evolutionarily conserved regions within SARS-CoV-2 proteome.
2024· 2 citedOpen Access

Frequent Co-authors

Julia Kodysh(16), Cansu Cimen Bozkus(16), Denise Rodriguez(16), Nina Bhardwaj(16), Anna Kaminska(15), Timothy J. O’Donnell(15), Mansi Saxena(14), Thomas U. Marron(14), John P. Finnigan(14), Sayali Onkar(14), Kevin Tuballes(14), Ruiwei Guo(14), Marcia Meseck(14), Robert Sebra(14), Samir Parekh(14), Matthew D. Galsky(14), Ana Blasquez(14), Gustavo Giménez(14), Mesude Bicak(14), Ana Acuña-Villaorduña(14)